Loading...
Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
Attard, Gerhardt Brown, LC Clarke, N Murphy, L Cross, W Jones, R Gillessen, S Russell, JM Cook, A Bowen, J
Attard, Gerhardt
Brown, LC
Clarke, N
Murphy, L
Cross, W
Jones, R
Gillessen, S
Russell, JM
Cook, A
Bowen, J
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2021-09-01
Submitted date
Subjects
Alternative
Abstract
Citation
Attard, G., Brown, L.C., Clarke, N. et al. (2021) Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology, 32, S5, S1298.
Publisher
Journal
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Type
Other
Language
en
Description
This is an accepted manuscript of an abstract published by Elsevier in Annals of Oncology on 01/09/2021, available online: https://doi.org/10.1016/j.annonc.2021.08.2098
The accepted version of the publication may differ from the final published version.
Series/Report no.
ISSN
0923-7534
EISSN
1569-8041